Market Research Reports, Inc. has announced the addition of “Irritable Bowel Syndrome - Pipeline Review, H1 2018” research report to their website www.MarketResearchReports.com

Lewes, DE -- (SBWire) -- 06/26/2018 --Irritable Bowel Syndrome - Pipeline Review, H1 2018, provides an overview of the Irritable Bowel Syndrome (Gastrointestinal) pipeline landscape.

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that affects large intestine (colon). Symptoms include cramping, abdominal pain, bloating gas, diarrhea, backache, muscle pains, poor appetite and constipation. These symptoms can be triggered by food, stress and hormones. Risk factors include age and family history. Treatment includes anti-diarrheal, anticholinergic, antidepressant and antibiotics medications.

Report Highlights
Irritable Bowel Syndrome - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 9, 6, 1, 8 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 120 pages "Irritable Bowel Syndrome - Pipeline Review, H1 2018" report covers Introduction, Report Coverage, Irritable Bowel Syndrome - Overview, Irritable Bowel Syndrome - Therapeutics Development, Irritable Bowel Syndrome - Therapeutics Assessment, Irritable Bowel Syndrome - Companies Involved in Therapeutics Development, Irritable Bowel Syndrome - Drug Profiles, Irritable Bowel Syndrome - Dormant Projects, Appendix. This report Covered Companies - 4D Pharma PLC, Allergan Plc, Ardelyx Inc, ConSynance Therapeutics Inc, Cosmo Pharmaceuticals NV, Dong-A ST Co Ltd, Eisai Co Ltd, Enterome Bioscience SA, GlaxoSmithKline Plc, ImmuneBiotech AB, Ironwood Pharmaceuticals Inc, Kissei Pharmaceutical Co Ltd, Metacrine Inc, Napo Pharmaceuticals Inc, RaQualia Pharma Inc, RedHill Biopharma Ltd, SK Biopharmaceuticals Co Ltd, Sumitomo Dainippon Pharma Co Ltd, Synthetic Biologics Inc, Vitality Biopharma Inc.

Please visit this link for more details: https://www.marketresearchreports.com/global-markets-direct/irritable-bowel-syndrome-pipeline-review-h1-2018

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Related Reports;

Interleukin 1 (IL1) - Pipeline Review, H1 2018 - Visit at - https://www.marketresearchreports.com/global-markets-direct/interleukin-1-il1-pipeline-review-h1-2018

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H1 2018 - Visit at - https://www.marketresearchreports.com/global-markets-direct/vancomycin-resistant-enterococcus-faecium-infections-pipeline-review-h1-2018

About Market Research Reports, Inc.
Market Research Reports® Inc. is world's largest store offering quality market research, SWOT analysis, competitive intelligence and industry reports. We help Fortune 500 to Start-Ups with the latest market research reports on global & regional markets which comprise key industries, leading market players, new products and latest industry analysis & trends.

Contact us for your market research requirements: https://www.marketresearchreports.com/contact